N-(2-(苄基氨基)乙基)-4-(萘-1-磺酰胺基)苯甲酰胺

Molbank Pub Date : 2024-07-25 DOI:10.3390/m1856

Rosalba Leuci, Fulvio Loiodice, L. Piemontese

{"title":"N-(2-(苄基氨基)乙基)-4-(萘-1-磺酰胺基)苯甲酰胺","authors":"Rosalba Leuci, Fulvio Loiodice, L. Piemontese","doi":"10.3390/m1856","DOIUrl":null,"url":null,"abstract":"In this study, we report the synthesis of N-(2-(benzylamino)ethyl)-4-(naphthalene-1-sulfonamido)benzamide, designed on the basis of the structures of the PPARγ partial agonist SR2067 and of the commercial acetylcholinesterase inhibitor drug donepezil, aiming for a multi-target approach for the therapy of elderly diseases, such as diabetes and Alzheimer’s disease. The compound was fully characterized by using 1H and 13C NMR, FT-IR and HRMS.","PeriodicalId":509184,"journal":{"name":"Molbank","volume":"8 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"N-(2-(Benzylamino)ethyl)-4-(naphthalene-1-sulfonamido)benzamide\",\"authors\":\"Rosalba Leuci, Fulvio Loiodice, L. Piemontese\",\"doi\":\"10.3390/m1856\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this study, we report the synthesis of N-(2-(benzylamino)ethyl)-4-(naphthalene-1-sulfonamido)benzamide, designed on the basis of the structures of the PPARγ partial agonist SR2067 and of the commercial acetylcholinesterase inhibitor drug donepezil, aiming for a multi-target approach for the therapy of elderly diseases, such as diabetes and Alzheimer’s disease. The compound was fully characterized by using 1H and 13C NMR, FT-IR and HRMS.\",\"PeriodicalId\":509184,\"journal\":{\"name\":\"Molbank\",\"volume\":\"8 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molbank\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/m1856\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molbank","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/m1856","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本研究报告了 N-(2-(苄基氨基)乙基)-4-(萘-1-磺酰胺基)苯甲酰胺的合成，该化合物是在 PPARγ 部分激动剂 SR2067 和商用乙酰胆碱酯酶抑制剂药物多奈哌齐的结构基础上设计的，旨在采用多靶点方法治疗糖尿病和阿尔茨海默病等老年疾病。利用 1H 和 13C NMR、傅立叶变换红外光谱以及 HRMS 对该化合物进行了全面表征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

N-(2-(Benzylamino)ethyl)-4-(naphthalene-1-sulfonamido)benzamide

In this study, we report the synthesis of N-(2-(benzylamino)ethyl)-4-(naphthalene-1-sulfonamido)benzamide, designed on the basis of the structures of the PPARγ partial agonist SR2067 and of the commercial acetylcholinesterase inhibitor drug donepezil, aiming for a multi-target approach for the therapy of elderly diseases, such as diabetes and Alzheimer’s disease. The compound was fully characterized by using 1H and 13C NMR, FT-IR and HRMS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Molbank

自引率

0.00%

发文量